Tebentafusp
Brand Names: Kimmtrak
Methodology & AI Transparency ⓘ
Tebentafusp Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage kimmtrak: is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
- 2 Real-world patient consensus: Tracked across 7 patient dosage logs with a 92% satisfaction benchmark (RxCUI 2590748).
- 3 Typical cash cost range: Dispensing cost comparison spans $63.58 mail/discount cash up to $155.77 uninsured retail (federal NADAC $1.3600).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Tebentafusp include nausea (9.6%), headache (11.8%), fatigue (7.3%).
Ask our AI Specialists anything about Tebentafusp
Tebentafusp Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage kimmtrak: is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma ( 1 , 2.1 ).
12.1 Mechanism of Action Tebentafusp-tebn is a bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor CD3 T cell engager. The TCR arm binds to a gp100 peptide presented by human leukocyte antigen-A*02:01 (HLA-A*02:01) on the cell surface of uveal melanoma tumor cells. In vitro, tebentafusp-tebn bound to HLA-A*02:01-positive uveal melanoma cells and activated polyclonal T cells to release inflammatory cytokines and cytolytic proteins, which results in direct lysis of uveal melanoma tumor cells.
Following administration (100 ug/.5mL Injection, Solution, Concentrate), Tebentafusp achieves Complete (~100%) parenteral systemic delivery for Tebentafusp (100 ug/.5mL Injection, Solution, Concentrate) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after tebentafusp administration onset, governed by a Approximately 9–20 hours terminal plasma half-life for Tebentafusp terminal half-life through phase i/ii hepatic conjugation of tebentafusp coupled with glomerular and tubular renal excretion.
Before initiating Tebentafusp at 100 ug/.5mL Injection, Solution, Concentrate, clinical safety checklists rule out severe drug-induced hypersensitivity to tebentafusp or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-08-20 for tebentafusp. Logged tolerability patterns center on headache (11.8% of reports), nausea (9.6% of reports), fatigue (7.3% of reports).
Assess baseline hepatic panels and interacting prescriptions when starting Tebentafusp (bispecific gp100 peptide-hla-directed cd3 t cell engager).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Tebentafusp dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Tebentafusp or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-08-20 for Tebentafusp
Logged Side-Effect Incidence (7 Reports)
Tebentafusp Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tebentafusp)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line Tebentafusp was previously shown to provide an OS benefit compared to checkpoint inhibitors or chemotherapy in untreated mUM. Annals of oncology : official journal of the European Society for Medical Oncology • 2024-03-15 • Phase III Randomized Trial | N = 52 | 82/100 | PMID 38048850 ↗ |
| Can This Approach Help? Inside the Latest Research on Cost-effectiveness analysis of an orphan drug tebentafusp in patients with For treatment-naive patients with mUM, the cost of tebentafusp therapy was not worth the improvement in survival benefits at the current price compared to the investigator's choice of therapy. Melanoma research • 2023-12-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37650713 ↗ |
Tebentafusp Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.3600/unit (~$40.80/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $155.77 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 7 Anonymous DotMD Community Micro-Logs | $63.58 / mo | View logs ↓ |
Tebentafusp Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Tebentafusp RxNorm Concept ID | 2590748 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.3600 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $155.77 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $63.58 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (7 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Tebentafusp Patient Community, Cohort Filters & Dosage Logs
Deterministic Tebentafusp reference combining NIH RxNorm (2590748), Medicaid NADAC ($1.3600/unit), and anonymous cohort outcomes (92% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Tebentafusp community threads and patient logs by age, biological sex, dosage, and treatment duration.